Skip to main content

Table 1 The baseline characteristics of included studies and recruited patients

From: Comparison of efficacy and safety of drug-eluting versus uncoated balloon angioplasty for femoropopliteal arterial occlusive disease: a meta-analysis

Study

Country

Sample size

Mean age (years)

Men (%)

Smoker (%)

DM (%)

Hyperlipidemia (%)

Hypertension (%)

ABI

Mean lesion (cm)

Intervention and control

Follow-up duration

Study quality

AcoArt I 2016 [17]

China

200

65.8

73.5

31.0

55.5

28.0

67.0

0.46

14.9

Paclitaxel-coated (3.0 μg/mm2) and standard uncoated balloon catheters

6 and 12 months

4

BIOLUX P-I 2015 [18]

Germany

60

70.8

56.7

68.8

33.4

61.7

73.4

0.70

6.0

Paclitaxel-coated (3.0 μg/mm2) balloon or the uncoated balloon

6 and 12 months

3

BIOLUX P-II 2015 [19]

Germany

72

71.3

79.2

55.6

66.7

68.1

86.1

NA

NA

Passeo-18 Lux paclitaxel-coated (3.0 μg/mm2) drug-eluting balloon or Passeo-18 percutaneous transluminal angioplasty

6 and 12 months

3

CONSEQUENT 2017 [20]

Germany

153

68.1

68.0

47.7

36.6

54.4

78.4

NA

13.2

Paclitaxel-coated (3.0 μg/mm2) balloons or plain old balloon angioplasty

6, 12, and 24 months

4

DEBATE-SFA 2013 [21]

Italy

104

75.0

69.2

51.0

74.0

57.7

88.5

0.32

9.5

Paclitaxel-eluting (3.0 μg/mm2) balloon plus bare-metal stent or percutaneous transluminal angioplasty plus bare-metal stent

12 months

4

DEBELLUM 2012 [22]

Italy

50

67.0

74.0

62.0

44.0

58.0

68.0

0.56

7.5

Paclitaxel-eluting (3.5 μg/mm2) balloon or angioplasty balloon

6 and 12 months

4

ILLUMENATE Pivotal 2017 [23]

US, Austria

300

68.8

58.7

81.0

50.3

88.7

93.7

0.75

8.3

Stellarex Drug-Coated (2.0 μg/mm2) Balloon or percutaneous transluminal angioplasty

12 months

3

ILLUMENATE European 2017 [24]

Germany, Austria

299

66.4

69.9

86.3

36.5

62.2

77.9

0.71

7.2

Low-dose paclitaxel coated (2.0 μg/mm2) balloon or percutaneous transluminal angioplasty

12 months

3

IN.PACT SFA 2015 [25]

US, Europe

331

67.7

65.9

37.8

43.2

83.7

90.3

0.76

8.9

Paclitaxel-coated (3.5 μg/mm2) balloons or percutaneous transluminal angioplasty

12 and 24 months

4

IN.PACT 2017 [26]

Belgium

106

70.5

65.1

57.5

100.0

73.6

88.7

NA

7.6

Paclitaxel-coated (3.5 μg/mm2) balloons or plain old balloon angioplasty

6 months

3

ISAR-STATH 2017 [27]

Germany

100

69.4

70.0

70.0

25.0

90.0

80.0

0.75

7.1

Paclitaxel-coated (3.5 μg/mm2) balloons or plain balloon angioplasty

6 and 24 months

3

LEVANT I2014 [28]

Germany

101

68.5

67.3

34.7

47.5

64.4

91.1

0.64

8.0

Lutonix paclitaxel-coated (2.0 μg/mm2) balloons or uncoated balloons

6, 12, and 24 months

4

LEVANT 22015 [29]

US, Europe

476

68.2

63.0

34.7

42.9

88.4

88.7

0.74

NA

Paclitaxel-coated (2.0 μg/mm2) balloon or standard angioplasty

12 months

4

PACIFIER 2012 [30]

Germany

91

71.0

61.5

53.8

35.2

48.4

65.9

0.69

6.8

Paclitaxel-coated (3.5 μg/mm2) IN.PACT Pacific or uncoated Pacific balloons

6 and 12 months

4

PACUBA 2016 [31]

Austria

74

68.2

58.1

47.3

40.5

58.1

71.6

0.65

17.9

Paclitaxel-based drug-eluting (3.0 μg/mm2) balloon angioplasty or standard percutaneous transluminal angioplasty

6 and 12 months

4

THUNDER 2008 [32]

Germany

102

68.5

63.7

22.5

48.0

65.7

81.4

0.50

7.4

Paclitaxel-coated (3.0 μg/mm2) balloons or uncoated balloons

6, 12, and 24 months

3

FemPac 2008 [33]

Germany

87

68.7

59.8

41.4

47.1

57.5

79.3

0.70

4.3

Paclitaxel-coated (3.0 μg/mm2) balloons or uncoated balloons

6 and 24 months

3

  1. ABI Ankle-brachial index, DM Diabetes mellitus